Why Opus Genetics, Inc.’s (IRD) Stock Is Up 5.37%
As of Wednesday, October 07, Opus Genetics, Inc.’s IRD share price has surged by 5.37%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
Commentary & Analysis
Why Opus Genetics, Inc.’s (IRD) Stock Is Up 6.56%
As of Wednesday, September 30, Opus Genetics, Inc.’s IRD share price has surged by 6.56%, which has investors questioning if this is right time to sell.Michael Rose
Why Opus Genetics, Inc.’s (IRD) Stock Is Down 6.59%
As of Wednesday, September 23, Opus Genetics, Inc.’s IRD share price has dipped by 6.59%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Opus Genetics, Inc.’s (IRD) Stock Is Down 8.04%
As of Wednesday, September 23, Opus Genetics, Inc.’s IRD share price has dipped by 8.04%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Opus Genetics, Inc.’s (IRD) Stock Is Up 6.66%
As of Monday, September 21, Opus Genetics, Inc.’s IRD share price has surged by 6.66%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | IRD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $386.9 | $242.6 | 35% |
|
| Shares Out (Mil) | 111.4 | 54.0 | 64% |
|
| Institutional Ownership | 88.4% | 93.1% | 56% |
|
| Float (Mil) | 64.7 | 41.4 | 52% |
|
| Beta | 0.58 | 0.95 | 34% |
|
| Avg Daily Volume (000s) | 1,833 | 633 | 79% |
|
| Price Change (52-week) |
126.8% | 50.0% | 96% |
|
| Growth | IRD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (15.1%) | (10.1%) | 25% |
|
| EPS (5yr) | 31.5% | 15.8% | 83 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (40.4%) | (15.7%) | 11% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 12 | |
| Current EPS | ($0.153) | ($0.939) | ($0.715) | |
| Month Ago EPS | ($0.156) | ($0.965) | ($0.738) | |
| # Rev Up | 0 | 2 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.158) | ($1.002) | ($0.764) | |
| Year/Year Chg | 10.1% | 17.8% | (71.4%) | |
| Financials | IRD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $10 | $37 | 9% |
|
| Net Income (TTM) (Mil) | ($108) | ($44) | 10% |
|
| EPS (TTM) | ($1.289) | ($1.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($41) | ($34) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $36 | $4 | 37% |
|
| Enterprise Value (Q1) (Mil) | $382 | $177 | 31% |
|
| Valuation | IRD | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.33 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IRD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (291.9%) | 67.3% | 1% |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (163.5%) | (47.6%) | 3% |
|
| ROE | na | (54.9%) | na |
|
| Liabilities to Assets | 114.0% | 29.3% | 96% |
|
| F-Score | 2 | 3 | 7% |
|
Passing Stock Screens
As of 10/9/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.3% |
| +/- S&P 500: | +13.8 |
